NCOA4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Lenvatinib (SCHEMBL864638)	1.00	1/20
Cep-32496 (SCHEMBL1015932)	1.00	1/20
Lenvatinib (SCHEMBL1389214)	0.98	1/20
Lenvatinib (SCHEMBL865174)	0.94	1/20
SCHEMBL1011649	0.91	1/20
Lenvatinib (SCHEMBL3928020)	0.91	1/20
SCHEMBL1011900	0.90	1/20
SCHEMBL1013252	0.90	1/20
SCHEMBL1012434	0.88	1/20
SCHEMBL1248140	0.87	1/20
SCHEMBL1894427	0.86	1/20
SCHEMBL1894913	0.86	1/20
SCHEMBL864156	0.85	1/20
SCHEMBL863487	0.85	1/20
SCHEMBL1012302	0.85	1/20
SCHEMBL1248296	0.83	1/20
SCHEMBL1889234	0.83	1/20
SCHEMBL1895420	0.83	1/20
SCHEMBL1898731	0.83	1/20
SCHEMBL864110	0.82	1/20

Clinical trials — most relevant to NCOA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Fulvestrant in Metastatic Breast Cancer	PHASE4	UNKNOWN
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies	PHASE2	COMPLETED
Rosiglitazone to Reverse Metabolic Defects in Diabetes	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients	EARLY_PHASE1	RECRUITING
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Molecular Pathways Related to Short-term Fasting Response	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NCOA4 binder may also engage these)

Protein	Name	Similarity
Q802X2	—	1.000	Q802X2 →
Q5FWP7	—	1.000	Q5FWP7 →
Q5U4H9	—	0.996	Q5U4H9 →
Q6NZK5	—	0.990	Q6NZK5 →
Q6GNV6	—	0.990	Q6GNV6 →
Q9NYK6	—	0.989	Q9NYK6 →
A3KMW7	—	0.989	A3KMW7 →
Q58EL7	—	0.988	Q58EL7 →
Q0IIM1	—	0.988	Q0IIM1 →
Q5SZL2	—	0.988	Q5SZL2 →
Q60795	—	0.988	Q60795 →
Q8CCJ9	—	0.988	Q8CCJ9 →
Q6Y685	—	0.988	Q6Y685 →
Q8BM75	—	0.988	Q8BM75 →
O54968	—	0.987	O54968 →
Q96QP1	—	0.987	Q96QP1 →
PHF20	PHD finger protein 20	0.987	landscape →
A8MW92	—	0.987	A8MW92 →
Q71F56	—	0.987	Q71F56 →
Q6PUR7	—	0.987	Q6PUR7 →
Q8C115	—	0.987	Q8C115 →
A5PLL1	—	0.987	A5PLL1 →
Q2M243	—	0.987	Q2M243 →
Q6IE24	—	0.987	Q6IE24 →
Q05A80	—	0.987	Q05A80 →
Q80YR6	—	0.987	Q80YR6 →
Q99ME3	—	0.987	Q99ME3 →
Q5ZJK5	—	0.987	Q5ZJK5 →
Q28DE6	—	0.986	Q28DE6 →
E1BLP6	—	0.986	E1BLP6 →